1. Home
  2. ADAP

as 10-07-2025 12:47pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

Founded: 2008 Country:
United Kingdom
United Kingdom
Employees: N/A City: ABINGDON, OXFORDSHIRE
Market Cap: 21.3M IPO Year: 2015
Target Price: $1.02 AVG Volume (30 days): 139.0M
Analyst Decision: Hold Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.66 EPS Growth: N/A
52 Week Low/High: $0.04 - $0.96 Next Earning Date: 11-12-2025
Revenue: $65,084,999 Revenue Growth: -53.99%
Revenue Growth (this year): -80.98% Revenue Growth (next year): 24.70%

Stock Insider Trading Activity of Adaptimmune Therapeutics plc (ADAP)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Wood Gavin ADAP Chief Financial Officer Sep 2 '25 Sell $0.01 96,000 $950.40 0
Behbahani Ali ADAP N/A Aug 18 '25 Sell $0.01 14,671,794 $176,061.53 0
Behbahani Ali ADAP N/A Aug 15 '25 Sell $0.01 4,828,206 $53,110.27 0

Share on Social Networks: